Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 21.82% is 36% above its 5-year average of 16.03%, near the high end of its 5-year range (12.02%–21.82%).
As of the fiscal period ended Wednesday, December 31, 2025. 16.81% above its 12-month average of 18.68%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
21.82%
RETURN ON EQUITY (ROE) AVG TTM
18.68%
RETURN ON EQUITY (ROE) AVG 3Y
17.25%
RETURN ON EQUITY (ROE) AVG 5Y
16.03%
RETURN ON EQUITY (ROE) AVG 10Y
19.32%
RETURN ON EQUITY (ROE) AVG 15Y
18.48%
RETURN ON EQUITY (ROE) AVG 20Y
19.25%
CURRENT VS TTM AVG
+16.81%
CURRENT VS 3Y AVG
+26.53%
CURRENT VS 5Y AVG
+36.15%
CURRENT VS 10Y AVG
+12.96%
CURRENT VS 15Y AVG
+18.10%
CURRENT VS 20Y AVG
+13.36%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+100.37%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$22.23B
Return on Equity (ROE)
21.82%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$22.14B
Return on Equity (ROE)
-43.12%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
Market Cap
$22.45B
Return on Equity (ROE)
10.89%
TTM Avg
10.12%
3Y Avg
7.00%
5Y Avg
7.00%
Market Cap
$23.38B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$20.80B
Return on Equity (ROE)
-2.02%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
Market Cap
$23.72B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$25.02B
Return on Equity (ROE)
2.94%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$25.77B
Return on Equity (ROE)
10.79%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$18.52B
Return on Equity (ROE)
6.01%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $22.23B | 21.82% | 18.68% | 17.25% | 16.03% |
| Moderna, Inc. (MRNA)vs › | $22.14B | -43.12% | -32.64% | -13.90% | 0.25% |
| STERIS plc (STE)vs › | $22.45B | 10.89% | 10.12% | 7.00% | 7.00% |
| BioNTech SE (BNTX)vs › | $23.38B | -6.79% | -4.55% | 10.63% | 21.70% |
| Viatris Inc. (VTRS)vs › | $20.80B | -2.02% | -13.64% | -4.29% | -4.38% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.72B | 18.89% | 16.95% | 19.08% | 20.56% |
| Waters Corporation (WAT)vs › | $25.02B | 2.94% | 29.98% | 64.02% | 111.55% |
| Labcorp Holdings Inc. (LH)vs › | $25.77B | 10.79% | 9.71% | 9.35% | 12.84% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.52B | 6.01% | 6.40% | 5.73% | 4.16% |
| Incyte Corporation (INCY)vs › | $25.96B | 25.79% | 12.92% | 11.29% | 9.83% |
ROE
21.8%
ROA
19.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 18.81% |
| 2024-12-31 | 18.55% |
| 2023-12-31 | 16.46% |
| 2022-12-31 | 15.16% |
| 2021-12-31 | 12.02% |
| 2020-12-31 | 15.16% |
| 2019-12-31 | -3.76% |
| 2018-12-31 | 21.13% |
| 2017-12-31 | 19.88% |
| 2016-12-31 | 38.33% |
| 2015-12-31 | 40.74% |
| 2014-12-31 | 26.87% |
| 2013-12-31 | 13.38% |
| 2012-12-31 | 27.81% |
| 2011-12-31 | 22.97% |
| 2010-12-31 | 11.98% |
| 2009-12-31 | 2.98% |
| 2008-12-31 | -8.43% |
| 2007-12-31 | 6.71% |
| 2006-12-31 | 36.15% |
| 2005-12-31 | 23.63% |
| 2004-12-31 | 8.06% |
| 2003-12-31 | -5.94% |
| 2002-12-31 | -13.78% |
| 2001-12-31 | -18.99% |
| 2000-12-31 | -32.21% |
| 1999-12-31 | -62.50% |
| 1998-12-31 | -76.65% |
